News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
91,632 Results
Type
Article (6685)
Company Profile (43)
Press Release (84904)
Section
Business (27853)
Career Advice (129)
Deals (4005)
Drug Delivery (31)
Drug Development (14135)
Employer Resources (12)
FDA (2860)
Job Trends (2135)
News (49403)
Policy (6003)
Tag
Academia (425)
Allergies (22)
Alliances (8989)
Alzheimer's disease (240)
Antibody-drug conjugate (ADC) (26)
Approvals (2847)
Artificial intelligence (22)
Bankruptcy (18)
Best Places to Work (1813)
Biosimilars (54)
Biotechnology (29)
Breast cancer (40)
Cancer (283)
Career advice (111)
Cell therapy (57)
Clinical research (11267)
Collaboration (99)
Compensation (23)
COVID-19 (530)
C-suite (28)
Data (277)
Diabetes (21)
Diagnostics (519)
Drug pricing (16)
Earnings (9312)
Events (11605)
Executive appointments (65)
FDA (3044)
Funding (81)
Gene therapy (55)
GLP-1 (98)
Government (1288)
Healthcare (1943)
Immunology and inflammation (19)
Infectious disease (552)
Inflammatory bowel disease (40)
IPO (1820)
Job creations (387)
Job search strategy (108)
Layoffs (48)
Legal (555)
Lung cancer (60)
Lymphoma (19)
Manufacturing (74)
Medical device (1188)
Medtech (1189)
Mergers & acquisitions (2232)
Metabolic disorders (47)
Neuroscience (290)
NextGen Class of 2024 (702)
Non-profit (347)
Northern California (306)
Obesity (17)
Opinion (39)
Patents (16)
Peanut (19)
People (7878)
Phase I (3689)
Phase II (4700)
Phase III (4123)
Pipeline (144)
Policy (28)
Postmarket research (295)
Preclinical (1454)
Press Release (66)
Radiopharmaceuticals (34)
Rare diseases (44)
Real estate (917)
Regulatory (4600)
Research institute (388)
Series A (16)
Southern California (320)
Startups (572)
United States (2753)
Vaccines (144)
Date
Today (7)
Last 7 days (121)
Last 30 days (412)
Last 365 days (6535)
2024 (6386)
2023 (7004)
2022 (9135)
2021 (9522)
2020 (8199)
2019 (5879)
2018 (4538)
2017 (5093)
2016 (4649)
2015 (5315)
2014 (3766)
2013 (2930)
2012 (3020)
2011 (3172)
2010 (2597)
Location
Africa (91)
Asia (7401)
Australia (868)
California (721)
Canada (174)
China (104)
Colorado (28)
Delaware (22)
Europe (13681)
Florida (80)
Illinois (32)
Indiana (29)
Maryland (249)
Massachusetts (491)
Minnesota (37)
New Jersey (305)
New York (205)
North Carolina (157)
Northern California (306)
Ohio (29)
Pennsylvania (127)
South America (135)
Southern California (320)
Texas (86)
Washington State (63)
91,632 Results for "insitu biologics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
AbbVie and Umoja Biopharma Announce Strategic Collaboration to Develop Novel In-Situ CAR-T Cell Therapies
AbbVie (NYSE: ABBV), and Umoja Biopharma (Umoja), an early clinical-stage biotechnology company, today announced two exclusive option and license agreements to develop multiple in-situ generated CAR-T cell therapy candidates in oncology using Umoja’s proprietary VivoVecTM platform.
January 4, 2024
·
5 min read
Business
InSitu Biologics Announces License Agreement With Mayo Clinic For Co-Development of Anti-Cancer Therapeutics
InSitu Biologics, Inc. is pleased to announce that it has entered into an agreement with the Mayo Foundation for Medical Education and Research to further develop its prolonged-release drug delivery technology for anti-cancer therapeutics.
December 22, 2022
·
2 min read
BioMidwest
InSitu Biologics Shares Latest Investigational Work at ASRA Meeting - November 18, 2022
InSitu Biologics, Inc. will share the latest investigational work on its multi-phase drug delivery matrix at the upcoming 21st Annual Pain Medicine Meeting of the American Society of Regional Anesthesia on November 18th , 2022.
November 17, 2022
·
1 min read
Business
Dr. M. Yaman Joins InSitu Biologics Medical Advisory Board
InSitu Biologics is very pleased to announce the appointment of Dr. M. Yaman, FRCS, FACS, to its Medical Advisory Board.
April 22, 2022
·
2 min read
News
Webinar: Revolutionizing Biologics Discovery: Harnessing the Power of AI and Patent Data
This webinar explores the pivotal role of patent data in overcoming the data challenges faced by generative AI models in drug discovery, particularly for biologics. Watch now.
October 23, 2024
·
1 min read
·
BioSpace Insights
BioMidwest
InSitu Biologics Shares Latest Investigational Work at ASRA Meeting
InSitu Biologics, Inc. will share the latest investigational work on its hydrogel-lipid-microparticle matrix at the upcoming 47th Annual Regional and Acute Pain Medicine Meeting of the American Society of Regional Anesthesia in April 2022.
March 31, 2022
·
1 min read
Approvals
AstraZeneca Wins Rare Autoimmune Indication for Asthma Biologic Fasenra
With the FDA’s approval, Fasenra will compete with GSK’s Nucala, which in December 2017 became the first biologic approved for eosinophilic granulomatosis with polyangiitis.
September 19, 2024
·
2 min read
·
Tristan Manalac
BIOSECURE Act
WuXi Biologics Faces Uncertain Future in the U.S. After BIOSECURE Blow
WuXi AppTec looks to unload its Philadelphia manufacturing sites and WuXi Biologics slows its rapid expansion in the U.S. as the companies await the Senate’s review of the BIOSECURE Act that threatens to cut them off from U.S. biopharma.
October 8, 2024
·
5 min read
·
Ben Hargreaves
Press Releases
Biologics Market Size to Reach USD 699.5 Billion by 2032, Impelled by Emergence of Advanced Drug Delivery Systems
Biologics Market Outlook 2024-2032:
August 8, 2024
·
14 min read
China
WuXi Biologics Takes Net Profit Hit Despite Inking Record Number of New Projects
With the potential passage of the BIOSECURE Act looming, WuXi Biologics reported a 24% drop in net profit in the first half of 2024.
August 22, 2024
·
2 min read
·
Tristan Manalac
1 of 9,164
Next
